ATE464297T1 - Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz - Google Patents

Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz

Info

Publication number: ATE464297T1
Authority: AT; Austria
Prior art keywords: improved method; calcium salt; rosuvastatin calcium; producing rosuvastatin; producing
Prior art date: 2003-06-05

Application number

AT04735910T

Other languages

English (en)

Inventor

Jeffrey Norman Crabb

John Horbury

Nigel Philip Taylor

Original Assignee

Astrazeneca Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-05

Filing date

2004-06-03

Publication date

2010-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33512687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE464297(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-06-03 Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE464297T1 publication Critical patent/ATE464297T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT04735910T 2003-06-05 2004-06-03 Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz ATE464297T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0312896.4A GB0312896D0 (en)	2003-06-05	2003-06-05	Chemical process
GBGB0324793.9A GB0324793D0 (en)	2003-06-05	2003-10-24	Chemical process
PCT/GB2004/002373 WO2004108691A1 (en)	2003-06-05	2004-06-03	Improved production of rosuvastatin calcium salt

Publications (1)

Publication Number	Publication Date
ATE464297T1 true ATE464297T1 (de)	2010-04-15

Family

ID=33512687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04735910T ATE464297T1 (de)	2003-06-05	2004-06-03	Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz

Country Status (26)

Country	Link
US (1)	US8063213B2 (de)
EP (1)	EP1633727B1 (de)
JP (1)	JP4651615B2 (de)
KR (1)	KR101099934B1 (de)
CN (1)	CN100422157C (de)
AR (1)	AR044773A1 (de)
AT (1)	ATE464297T1 (de)
AU (1)	AU2004245291B2 (de)
BR (1)	BRPI0410922B8 (de)
CA (1)	CA2527314C (de)
CO (1)	CO5640116A2 (de)
DE (1)	DE602004026576D1 (de)
ES (1)	ES2341858T3 (de)
GB (2)	GB0312896D0 (de)
HK (1)	HK1087405A1 (de)
IL (1)	IL172075A (de)
IS (1)	IS2751B (de)
MX (1)	MXPA05013128A (de)
MY (1)	MY140820A (de)
NO (1)	NO332971B1 (de)
NZ (1)	NZ543962A (de)
RU (1)	RU2361864C2 (de)
SA (1)	SA04250223B1 (de)
TW (1)	TWI341310B (de)
UY (1)	UY28341A1 (de)
WO (1)	WO2004108691A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0011120D0 (en)	2000-05-09	2000-06-28	Avecia Ltd	Process
NL1015744C2 (nl) *	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
US7304156B2 (en)	2001-07-13	2007-12-04	Astrazeneca Uk Limited	Preparation of aminopyrimidine compounds
EP1323717A1 (de)	2001-12-27	2003-07-02	Dsm N.V.	Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
EP1375493A1 (de)	2002-06-17	2004-01-02	Dsm N.V.	Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
NZ540722A (en)	2002-12-16	2008-03-28	Astrazeneca Uk Ltd	Process for the preparation of pyrimidine compounds and intermediates thereof
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
US7851624B2 (en)	2003-12-24	2010-12-14	Teva Pharamaceutical Industries Ltd.	Triol form of rosuvastatin and synthesis of rosuvastatin
EP1737828A1 (de) *	2004-01-19	2007-01-03	Ranbaxy Laboratories Limited	Amorphe magnesiumsalze von rosuvastatin
GB0428328D0 (en) *	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
TWI345562B (en) *	2005-02-22	2011-07-21	Teva Pharma	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
EP1915349B2 (de)	2005-06-24	2018-09-12	LEK Pharmaceuticals d.d.	Verfahren zur herstellung von reinem amorphen rosuvastatin-calcium
CZ299215B6 (cs) *	2005-06-29	2008-05-21	Zentiva, A. S.	Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
JP2008515931A (ja)	2005-08-16	2008-05-15	テバファーマシューティカルインダストリーズリミティド	結晶形ロスバスタチン中間体
US20070099994A1 (en) *	2005-08-16	2007-05-03	Valerie Niddam-Hildesheim	Rosuvastatin calcium with a low salt content
HU227696B1 (en) *	2006-04-13	2011-12-28	Egyt Gyogyszervegyeszeti Gyar	Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2024341B1 (de)	2006-05-03	2015-12-02	MSN Laboratories Private Limited	Neue verfahren für statine und deren pharmazeutisch unbedenkliche salze
EP2086945B1 (de)	2006-10-09	2016-01-06	MSN Laboratories Private Limited	Neuartiges verfahren zur herstellung von statinen und ihren pharmazeutisch akzeptalen salzen
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process
HU230981B1 (hu) *	2007-10-12	2019-08-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Eljárás rosuvastatin só előállítására
WO2009143776A1 (zh)	2008-05-27	2009-12-03	常州制药厂有限公司	瑞舒伐他汀钙盐的制备方法及其中间体
PT2309992T (pt)	2008-06-27	2018-01-22	Krka Tovarna Zdravil D D Novo Mesto	Composição farmacêutica compreendendo uma estatina
EP2138165A1 (de)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmazeutische Zusammensetzung mit einem Statin
WO2010029561A1 (en) *	2008-09-09	2010-03-18	Biocon Limited	A process for preparation of rosuvastatin acetonide calcium
EP2373609B1 (de)	2008-12-19	2013-10-16	KRKA, D.D., Novo Mesto	Verwendung amphiphiler verbindungen zur kontrollierten kristallisation von statinen und statinzwischenprodukten
EP2327682A1 (de)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte.
EP2387561A4 (de)	2009-01-19	2012-07-25	Msn Lab Ltd	Verbessertes verfahren zur herstellung von hochreiner (3r,5s)-7-[2-cyclopropyl-4-(4-fluorphenyl) chinolin-3-yl]-3,5-dihydroxy-6(e)-heptensäure und pharmazeutisch akzeptable salze daraus
EP2526099B1 (de)	2010-01-18	2016-03-30	MSN Laboratories Limited	Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung
US8536330B2 (en)	2010-04-23	2013-09-17	Ranbaxy Laboratories Limited	Intermediates for the preparation of HMG-CoA reductase inhibitors
WO2012011129A2 (en) *	2010-07-22	2012-01-26	Msn Laboratories Limited	Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
CN105753834B (zh) *	2016-03-25	2018-08-21	河南师范大学	一种瑞舒伐他汀钙关键手性中间体的合成方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4645858A (en)	1982-03-22	1987-02-24	G. D. Searle & Co.	Pentanedioic acid derivatives
DE3741509A1 (de)	1987-12-08	1989-06-22	Hoechst Ag	Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
KR900701778A (ko)	1988-10-06	1990-12-04	예안 크라머, 한스 루돌프 하우스	피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물
US5026698A (en)	1988-11-02	1991-06-25	Nissan Chemical Industries, Ltd.	Thienopyridine type mevalonolactones
JP2648897B2 (ja) *	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
WO1993008823A1 (en)	1991-11-06	1993-05-13	Tanabe Seiyaku Co., Ltd.	Guanidinyl and related cell adhesion modulation compounds
US5278313A (en)	1992-03-27	1994-01-11	E. R. Squibb & Sons, Inc.	Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
ES2106926T3 (es)	1992-07-02	1997-11-16	Hoechst Ag	Procedimiento para la preparacion del ester terc-butilico del acido (3r,5s)6-hidroxi-3,5-o-isopropiliden-3,5-dihidroxi-hexanoico.
IL128862A (en)	1995-07-17	2007-12-03	Warner Lambert Co	[R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
US6278001B1 (en)	1995-11-28	2001-08-21	L'oréal	Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr)	1995-11-28	1997-12-26	Oreal	Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
ES2194202T3 (es)	1996-06-24	2003-11-16	Novartis Ag	Compuestos polimorfos.
CA2320163C (en)	1998-12-10	2008-09-23	Kaneka Corporation	Process for producing simvastatin
GB9900339D0 (en) *	1999-01-09	1999-02-24	Zeneca Ltd	Chemical compounds
GB9903472D0 (en) *	1999-02-17	1999-04-07	Zeneca Ltd	Chemical process
WO2001022962A1 (en)	1999-09-30	2001-04-05	Merck & Co., Inc.	Anti-hypercholesterolemic drug combination
CN1423634A (zh)	1999-11-17	2003-06-11	特瓦制药工业有限公司	阿托伐他汀钙的多晶型物
GB0001621D0 (en)	2000-01-26	2000-03-15	Astrazeneca Ab	Pharmaceutical compositions
GB0003305D0 (en) *	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
AU2000254249A1 (en)	2000-03-28	2001-10-08	Biocon India Limited	Synthesis of (r-(r,r))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) *	2000-05-09	2000-06-28	Avecia Ltd	Process
GB0011163D0 (en) *	2000-05-10	2000-06-28	Astrazeneca Ab	Chemical compound
NL1015744C2 (nl) *	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL155194A0 (en)	2000-10-05	2003-11-23	Biogal Pharmaceutical Co Ltd	Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
ES2313999T3 (es)	2000-11-16	2009-03-16	Teva Pharmaceutical Industries Ltd.	Hidrolisis de esteres del acido (r(r,r))-2-(4-fluorofenil)-beta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico con hidroxido calcico.
US6777552B2 (en)	2001-08-16	2004-08-17	Teva Pharmaceutical Industries, Ltd.	Processes for preparing calcium salt forms of statins
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl)	2001-03-09	2002-09-10	Synthon Bv	Een lactonisatie proces.
IN190564B (de)	2001-04-11	2003-08-09	Cadila Heathcare Ltd
PL367133A1 (en)	2001-06-06	2005-02-21	Bristol-Myers Squibb Company	Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
US7304156B2 (en) *	2001-07-13	2007-12-04	Astrazeneca Uk Limited	Preparation of aminopyrimidine compounds
PL370407A1 (en)	2001-08-16	2005-05-30	Teva Pharmaceutical Industries Ltd.	Processes for preparing calcium salt forms of statins
US20050032875A1 (en)	2001-08-22	2005-02-10	Heinz Wolleb	Process for the preparation of indole derivatives
EP1465667A4 (de)	2001-09-24	2007-06-27	Merck & Co Inc	Screening- und auswahlverfahren für statin-kombinationen
EP1323717A1 (de) *	2001-12-27	2003-07-02	Dsm N.V.	Prozess für die Herstellung von 2-(6-Substituierten-1,3-Dioxan-4-yl) Essigsäure Derivaten
KR100511533B1 (ko)	2002-04-09	2005-08-31	임광민	키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AR039836A1 (es)	2002-05-21	2005-03-02	Ranbaxy Lab Ltd	Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
EP1375493A1 (de)	2002-06-17	2004-01-02	Dsm N.V.	Verfahren zur Herstellung von Dioxanessigsäureester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
HUP0500851A3 (en)	2002-12-10	2008-02-28	Ranbaxy Lab Ltd	Process for the preparation of rosuvastatin
NZ540722A (en) *	2002-12-16	2008-03-28	Astrazeneca Uk Ltd	Process for the preparation of pyrimidine compounds and intermediates thereof
EA013500B1 (ru)	2003-04-11	2010-06-30	Лек Фармасьютиклз Д.Д.	Способ получения аморфной кальциевой соли аторвастатина
WO2004103977A2 (en)	2003-05-21	2004-12-02	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of pyrimidine derivatives
GB0312896D0 (en)	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
WO2005005384A1 (en)	2003-07-15	2005-01-20	Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S.	Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2657076A1 (en)	2003-08-28	2005-03-17	Teva Pharmaceutical Industries Ltd.	Process for the preparation of rosuvastatin calcium
UY28501A1 (es) *	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en)	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
US20070191318A1 (en)	2003-10-22	2007-08-16	Yatendra Kumar	Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en)	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
DE10352659B4 (de)	2003-11-11	2007-09-13	Ratiopharm Gmbh	Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
US7777034B2 (en)	2003-11-24	2010-08-17	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
DE602004032465D1 (de)	2003-12-02	2011-06-09	Teva Pharma	Referenzstandard zur charakterisierung von rosuvastatin
WO2005054207A1 (en)	2003-12-04	2005-06-16	Glenmark Pharmaceuticals Limited	Process for the preparation of pyrimidine derivatives
CA2550742A1 (en)	2003-12-24	2005-07-14	Teva Pharmaceutical Industries Ltd.	Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs)	2004-01-16	2005-08-17	Zentiva, A.S.	Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
EP1737828A1 (de)	2004-01-19	2007-01-03	Ranbaxy Laboratories Limited	Amorphe magnesiumsalze von rosuvastatin
EP1709008A1 (de)	2004-01-19	2006-10-11	Ranbaxy Laboratories Limited	Salze von hmg-coa-reduktase-inhibitoren und deren verwendung
US7241800B2 (en)	2004-03-17	2007-07-10	Mai De Ltd.	Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en)	2004-03-26	2004-04-28	Avecia Ltd	Process and compounds
US7161004B2 (en)	2004-06-21	2007-01-09	Dr. Reddy's Laboratories Limited	Processes to produce intermediates for rosuvastatin
CA2573857A1 (en)	2004-07-13	2006-02-16	Teva Pharmaceutical Industries Ltd.	A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
WO2006035277A2 (en)	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
JP2008528542A (ja)	2005-01-31	2008-07-31	チバホールディングインコーポレーテッド	ロスバスタチンカルシウム塩の結晶形
CA2498978A1 (en)	2005-02-28	2006-08-28	Apotex Pharmachem Inc.	An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process

2003
- 2003-06-05 GB GBGB0312896.4A patent/GB0312896D0/en not_active Ceased
- 2003-10-24 GB GBGB0324793.9A patent/GB0324793D0/en not_active Ceased
2004
- 2004-05-24 TW TW093114667A patent/TWI341310B/zh not_active IP Right Cessation
- 2004-06-02 UY UY28341A patent/UY28341A1/es not_active Application Discontinuation
- 2004-06-03 CA CA2527314A patent/CA2527314C/en not_active Expired - Fee Related
- 2004-06-03 MY MYPI20042138A patent/MY140820A/en unknown
- 2004-06-03 CN CNB2004800154822A patent/CN100422157C/zh not_active Expired - Lifetime
- 2004-06-03 RU RU2005138370/04A patent/RU2361864C2/ru active
- 2004-06-03 US US10/558,390 patent/US8063213B2/en active Active
- 2004-06-03 DE DE602004026576T patent/DE602004026576D1/de not_active Expired - Lifetime
- 2004-06-03 MX MXPA05013128A patent/MXPA05013128A/es active IP Right Grant
- 2004-06-03 AU AU2004245291A patent/AU2004245291B2/en not_active Expired
- 2004-06-03 WO PCT/GB2004/002373 patent/WO2004108691A1/en active Application Filing
- 2004-06-03 AT AT04735910T patent/ATE464297T1/de not_active IP Right Cessation
- 2004-06-03 ES ES04735910T patent/ES2341858T3/es not_active Expired - Lifetime
- 2004-06-03 KR KR1020057023329A patent/KR101099934B1/ko active IP Right Grant
- 2004-06-03 NZ NZ543962A patent/NZ543962A/en not_active IP Right Cessation
- 2004-06-03 EP EP04735910A patent/EP1633727B1/de not_active Expired - Lifetime
- 2004-06-03 BR BRPI0410922A patent/BRPI0410922B8/pt active IP Right Grant
- 2004-06-03 JP JP2006508394A patent/JP4651615B2/ja not_active Expired - Lifetime
- 2004-06-04 AR ARP040101944A patent/AR044773A1/es unknown
- 2004-07-14 SA SA04250223A patent/SA04250223B1/ar unknown
2005
- 2005-11-21 IL IL172075A patent/IL172075A/en active IP Right Grant
- 2005-12-02 CO CO05122683A patent/CO5640116A2/es unknown
- 2005-12-05 NO NO20055730A patent/NO332971B1/no not_active IP Right Cessation
2006
- 2006-01-02 IS IS8217A patent/IS2751B/is unknown
- 2006-07-05 HK HK06107580.5A patent/HK1087405A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
MXPA05013128A (es)	2006-03-16
BRPI0410922B1 (pt)	2016-02-23
TWI341310B (en)	2011-05-01
CA2527314C (en)	2012-02-21
CA2527314A1 (en)	2004-12-16
ES2341858T3 (es)	2010-06-29
US20080221323A1 (en)	2008-09-11
JP2006526602A (ja)	2006-11-24
IL172075A (en)	2011-06-30
AR044773A1 (es)	2005-10-05
RU2005138370A (ru)	2006-07-10
EP1633727B1 (de)	2010-04-14
CN100422157C (zh)	2008-10-01
IS8217A (is)	2006-01-02
IS2751B (is)	2011-09-15
MY140820A (en)	2010-01-29
CN1798741A (zh)	2006-07-05
NZ543962A (en)	2008-09-26
RU2361864C2 (ru)	2009-07-20
SA04250223B1 (ar)	2008-12-23
WO2004108691A1 (en)	2004-12-16
BRPI0410922A (pt)	2006-06-27
UY28341A1 (es)	2005-01-31
HK1087405A1 (en)	2006-10-13
JP4651615B2 (ja)	2011-03-16
NO20055730D0 (no)	2005-12-05
KR101099934B1 (ko)	2011-12-28
GB0312896D0 (en)	2003-07-09
NO332971B1 (no)	2013-02-11
GB0324793D0 (en)	2003-11-26
AU2004245291B2 (en)	2008-02-14
NO20055730L (no)	2005-12-27
EP1633727A1 (de)	2006-03-15
KR20060017848A (ko)	2006-02-27
DE602004026576D1 (de)	2010-05-27
AU2004245291A1 (en)	2004-12-16
BRPI0410922B8 (pt)	2021-05-25
TW200510337A (en)	2005-03-16
US8063213B2 (en)	2011-11-22
CO5640116A2 (es)	2006-05-31

Publication	Publication Date	Title
ATE464297T1 (de)	2010-04-15	Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
ATE501125T1 (de)	2011-03-15	Verfahren zur herstellung des calciumsalzes von rosuvastatin
ATE340819T1 (de)	2006-10-15	Verfahren zur herstellung von polyamiden
ATE408609T1 (de)	2008-10-15	Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE408604T1 (de)	2008-10-15	Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
ATE399761T1 (de)	2008-07-15	Verfahren zur herstellung von dinitrilen
DE602005019848D1 (de)	2010-04-22	Verfahren zur herstellung von tad- getrocknetem ti
ATE440888T1 (de)	2009-09-15	Verfahren zur herstellung von glatiramer
ATE515500T1 (de)	2011-07-15	Verfahren zur herstellung von telmisartan
ATE353322T1 (de)	2007-02-15	Verfahren zur herstellung von 2- (chinoxalin-5- ylsulfonylamino) -benzamid-verbindungen
ATE489015T1 (de)	2010-12-15	Verfahren zur herstellung von verschlüssen
ATE476411T1 (de)	2010-08-15	Verfahren zur herstellung von 3-pentennitril
ATE444303T1 (de)	2009-10-15	Verfahren zur herstellung von ferrisuccinylcasein
ATE308524T1 (de)	2005-11-15	Verfahren zur herstellung von aripiprazole
DE60330050D1 (de)	2009-12-24	Verfahren zur herstellung von pyrimidinverbindungen
DE50308650D1 (de)	2008-01-03	Verfahren zur herstellung von cellulosecarbamatformkörpern
ATE376997T1 (de)	2007-11-15	Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
DE602004022134D1 (de)	2009-09-03	Verfahren zur herstellung von dinitrilen
ATE417839T1 (de)	2009-01-15	Verfahren zur herstellung von amorolfin
ATE460414T1 (de)	2010-03-15	Verfahren zur herstellung von tiotropiumsalzen
DE50303611D1 (de)	2006-07-06	Verfahren zur herstellung von polyisobuten
DE502004004318D1 (de)	2007-08-23	Verfahren zur herstellung von metall-matrix-verbundwerkstoffen
ATE549314T1 (de)	2012-03-15	Verfahren zur herstellung von 4-aminochinazolinen
ATE402138T1 (de)	2008-08-15	Verfahren zur herstellung von 2- aminoindanderivaten
ATE430140T1 (de)	2009-05-15	Verfahren zur herstellung von ä1,4,5ü- oxadiazepinderivaten

Legal Events

Date	Code	Title	Description
2010-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties